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ABSTRACT
Background
The genetic differences among HIV-1 subtypes may be critical to clinical management and
drug resistance surveillance as antiretroviral treatment is expanded to regions of the world
where diverse non-subtype-B viruses predominate.
Methods and Findings
To assess the impact of HIV-1 subtype and antiretroviral treatment on the distribution of
mutations in protease and reverse transcriptase, a binomial response model using subtype and
treatment as explanatory variables was used to analyze a large compiled dataset of non-
subtype-B HIV-1 sequences. Non-subtype-B sequences from 3,686 persons with well
characterized antiretroviral treatment histories were analyzed in comparison to subtype B
sequences from 4,769 persons. The non-subtype-B sequences included 461 with subtype A,
1,185 with C, 331 with D, 245 with F, 293 with G, 513 with CRF01_AE, and 618 with CRF02_AG.
Each of the 55 known subtype B drug-resistance mutations occurred in at least one non-B
isolate, and 44 (80%) of these mutations were significantly associated with antiretroviral
treatment in at least one non-B subtype. Conversely, of 67 mutations found to be associated
with antiretroviral therapy in at least one non-B subtype, 61 were also associated with
antiretroviral therapy in subtype B isolates.
Conclusion
Global surveillance and genotypic assessment of drug resistance should focus primarily on
the known subtype B drug-resistance mutations.
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The HIV-1 pandemic resulted from the cross-species
transmission of a lentivirus, most likely of chimpanzee origin,
that began spreading among humans during the ﬁrst half of
the previous century [1,2,3]. The progeny of this zoonotic
infection—designated HIV-1 group M (main) viruses—make
up the vast majority of HIV-1 infections. During their spread
among humans, group M viruses have developed an extra-
ordinary degree of genetic diversity, and most can be
segregated into nine pure subtypes and several commonly
circulating recombinant forms [4].
HIV-1 subtype B is the predominant subtype in North
America, Western Europe, and Australia. The antiretroviral
drugs used to treat HIV were developed using biophysical,
biochemical, and in vitro studies of subtype B isolates, and
most data on the genetic mechanisms of HIV-1 drug
resistance are from subtype B viruses. However, HIV-1
subtype B viruses account for only approximately 12% of
the global HIV pandemic [5], and as therapy is introduced
into developing countries, the number of persons with non-B
viruses initiating therapy will increase dramatically.
HIV-1 subtypes differ from one another by 10%–12% of
their nucleotides and 5%–6% of their amino acids in
protease and reverse transcriptase (RT) [6]. Intersubtype
nucleotide differences inﬂuence the spectrum of amino acid
substitutions resulting from point mutations, and intersub-
type amino acid differences inﬂuence the biochemical and
biophysical microenvironment within the protease and RT
[7,8]. These differences among subtypes therefore could
inﬂuence the spectrum of mutations that develop during
selective drug pressure.
An increasing number of observational studies, in vitro and
in vivo, suggest that the currently available protease and RT
inhibitors are as active against non-B viruses as they are
against subtype B viruses [9,10,11,12,13,14,15,16,17,18,19,20,
21,22,23,24,25,26]. However, fewer data are available on the
genetic mechanisms of drug resistance in non-B viruses, and
some in vitro and in vivo observations suggest that the various
subtypes may respond differently to certain antiretroviral
drugs [27,28,29,30,31,32,33,34,35].
Identifying the relevant drug-resistance mutations among
non-B subtypes will be important for monitoring the
evolution and transmission of drug resistance, for determin-
ing initial treatment strategies for persons infected with non-
B viruses, and for interpreting genetic resistance among
patients who fail antiretroviral therapy.
In this study, we characterize protease and RT mutations in
non-B HIV-1 subtypes from persons receiving antiretroviral
therapy, and attempt to answer the following two questions.
(i) Do the mutations that cause drug resistance in subtype B
viruses also develop in non-B viruses exposed to antiretro-
viral drugs? (ii) Do novel mutations emerge in non-subtype-B
viruses during antiretroviral drug failure that are not
recognized in subtype B viruses?
Methods
HIV-1 Sequences and Antiretroviral Treatments
Sequences of HIV-1 protease (positions 1–99) and RT
(positions 1–240) from persons whose antiretroviral treat-
ment history was known were collected from the published
literature and from 14 laboratories in 12 countries. Persons
were considered untreated if they had never been exposed to
antiretroviral drugs, and treated if they were receiving RT
inhibitors (RTIs) and/or protease inhibitors (PIs) at the time
the isolate was obtained. Sequences from treated persons
were included for analysis only if they were obtained from
persons whose entire treatment histories were known. If
multiple isolates from the same person were sequenced, only
the latest isolate was included for analysis. Only sequences
determined using dideoxyterminator sequencing were in-
cluded in the analysis. In all, 99% of sequences were
determined using direct PCR (population-based sequencing),
and 1% of sequences represented the consensus sequence of
multiple clones.
Samples obtained from patients were submitted to clinical
and research laboratories for resistance testing in the course
of evaluation and care of HIV infection. Data analyzed
included published and presented data obtained under
protocols approved by national and local institutional review
boards or ethical review panels in each country. Sequence,
demographic, and treatment data, unlinked from all personal
identiﬁers, were analyzed at Stanford University under a
protocol approved by the Stanford University Panel on
Human Subjects.
Subtype Assignment
Similarity plotting and bootscanning using a window size of
400 nucleotides and a step size of 40 nucleotides were
performed using reference sequences for each of the nine
pure subtypes (A, B, C, D, F, G, H, J, and K) and two
recombinant forms (CRF01_AE and CRF02_AG) [36].
Isolates that contained a combination of more than one
subtype were excluded from analysis, except when subtypes A
and G were detected in a pattern consistent with CRF02_AG.
Because CRF01_AE pol sequences do not contain recombi-
nant breakpoints, subtype assignment was based on the fact
that pol CRF01_AE and pure A sequences are divergent. This
approach had an accuracy of 96% when applied to the
protease and RT genes of 137 well characterized subtype A,
CRF01_AE, and CRF02_AG isolates with known subtypes
based on pol and gag and/or env, with most errors resulting
from the misclassiﬁcation of subtype A protease sequences as
CRF01_AE (data not shown).
Reference sequences used were U455 (subtype A), CM240
(CRF01_AE), IbNG (CRF02_AG), HXB2 (subtype B), C2220
(subtype C), NDK (subtype D), 93BR020 (subtype F), SE6165
(subtype G), 90CR056 (subtype H), SE9173c (subtype J),
97EQTB11C (subtype K), YBF30 (Group N), and ANT70C
(Group O). A total of 223 protease and 307 RT sequences of
indeterminate subtype were excluded from the analysis.
Mutation Definitions
Each sequence was translated and compared to the
consensus B protease and RT sequences in the Los Alamos
HIV Sequence database (http://hiv-web.lanl.gov) using the
HIVSeq program [37]. Mutations were deﬁned as differences
from the wild-type consensus B sequence. Known subtype B
drug-resistance mutations were deﬁned as follows: 18 nucleo-
side RTI (NRTI)–resistance positions at 41, 44, 62, 65, 67, 69,
70, 74, 75, 77, 115, 116, 118, 151, 184, 210, 215, and 219; 15
non-nucleoside RTI (NNRTI)–resistance positions at 98, 100,
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Subtype and Drug Impact on Genotype101, 103, 106, 108, 179, 181, 188, 190, 225, 227, 230, 236, and
238; and 22 protease inhibitor (PI)–resistance positions at 10,
20, 24, 30, 32, 33, 36, 46, 47, 48, 50, 53, 54, 63, 71, 73, 77, 82, 84,
88, 90, and 93 [38,39]. Mutations also included differences
from consensus B that were present as part of a nucleotide
mixture.
Polymorphisms were deﬁned as mutations that occurred in
more than 1% of sequences from untreated persons.
Subtype-speciﬁc polymorphisms were deﬁned as mutations
that were signiﬁcantly more prevalent in each non-B subtype
than in subtype B viruses from untreated persons. Subtype-
speciﬁc treatment-related mutations were deﬁned as muta-
tions that were signiﬁcantly more prevalent in HIV-1 isolates
from treated persons than in isolates from untreated persons
infected with the same subtype.
Quality Control
Phylogenetic analysis to detect duplicate sequences iden-
tiﬁed 23 pairs of identical sequences and 1,039 pairs of
sequences that differed from one another by no more than
1% of their nucleotides. To reduce the likelihood that isolates
from different persons with similar mutations resulted from
duplicate reporting, laboratory contamination, or HIV-1
transmission, only one sequence from each of these 1,062
sequence pairs was included in the analyses in this study.
Although all extant HIV-1 isolates are epidemiologically
linked through chains of transmission, protease or RT
sequences that diverge by 1% or less appear to be more
likely to result from direct transmission than those that
diverge by more than 1% [40].
To distinguish mutations developing in multiple individu-
als from mutations that developed in a smaller number of
founder viruses, we reconstructed the ancestral sequences at
each node of the phylogenetic trees for each subtype and
counted the number of times each mutation was predicted to
have developed within a subtype. Mutations for which
founder viruses accounted for 75% or more of occurrences
(i.e., the number of branches on which the mutation has
developed divided by the number of sequences with the
mutation is less than 75%) were not considered treatment-
Figure 1. Binomial Response Model Used to Evaluate Subtype and
Treatment Effects on Genotypic Evolution for Each Protease and RT
Position
A separate model was created for each non-B subtype. The
frequencies of mutations at each position in four patient groups
(untreated subtype B, treated subtype B, untreated non-B, and
treated non-B) were converted to Y scores using a cube root
transformation (similar to a logistic transform). Subtype effect was
evaluated by calculating h1, the score differences between non-B and
B subtypes in untreated persons. The treatment effect was evaluated
by calculating h2, the score differences between treated and untreated
persons within the same subtype. The subtype–treatment interaction
was evaluated by calculating h3, the difference of differences in the 2
32 table, or the difference in treatment effects between non-B and B
subtypes.
DOI: 10.1371/journal.pmed.0020112.g001
Figure 2. Number of Treated and Untreated Persons Infected with B and
Non-B HIV-1 Subtypes from Whom Protease and/or RT Sequences Were
Available for Analysis.
DOI: 10.1371/journal.pmed.0020112.g002
Table 1. Geographical Origin of Persons Infected with Non-B
Subtypes
Subtype Country
A Uganda (215), United Kingdom (49), Kenya (41), Rwanda (34),
Canada (23), France (21), Belgium (14), Sweden (10),
Cameroon (10), Other (43)
C India (225), South Africa (220), United Kingdom (145),
Brazil (106), Canada (93), Zimbabwe (71), Israel (59),
Botswana (42), Zambia (29), Sweden (29), Belgium (24), Uganda (19),
Denmark (17), Burundi (16), France (14), Other (73)
D Uganda (189), Cameroon (21), Cuba (21), Kenya (20),
Canada (18), United Kingdom (14), Other (46)
F Brazil (127), Romania (46), Cameroon (21), Cuba (10),
Other (40)
G Portugal (193), Cameroon (20), Spain (14), France (14),
Other (53)
CRF01_AE Thailand (260), Vietnam (98), Japan (35), Cameroon (27),
Canada (11), United Kingdom (10), Uganda (10), France (10),
Other (52)
CRF02_AG Cameroon (207), Ivory Coast (128), France (47), Spain (46),
Portugal (37), Senegal (24), United Kingdom (18), Italy (12),
Belgium (12), Canada (11), Gabon (10), Other (63)
Others
a Cameroon (14), Other (26)
Numbers of persons from countries for which ten or more sequences were available are shown in parentheses.
aSubtypes H, J, and K.
DOI: 10.1371/journal.pmed.0020112.t001
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created using the neighbor-joining method using the HKY85
model with gamma distribution within PAUP
* version 4.0b10
for each subtype and each gene. Ancestral sequences were
reconstructed using MESQUITE version 1.02 (http://www.
mesquiteproject.org).
To further reduce the inﬂuence of transmitted drug
resistance on this analysis and to exclude the possibility that
some untreated persons were classiﬁed incorrectly, sequences
from untreated persons containing two or more non-
polymorphic resistance mutations were excluded from the
analysis. This approach was predicated on the strong like-
lihood that the presence of two mutations at highly conserved
sites in untreated persons does not reﬂect natural variation in
protease or RT but rather is most consistent with previous
selective drug pressure. Based on this criterion, 23 protease
and 25 RT sequences from 47 persons were excluded from the
analysis: 22 CRF01_AE sequences, 15 subtype C sequences,
six CRF02_AG sequences, ﬁve subtype G sequences, four
subtype A sequences, three subtype F sequences, and one
subtype D sequence. The mutations in the excluded sequences
consisted almost entirely of the NRTI-resistance mutations at
positions 41, 67, 70, 210, 215, and 219; the NNRTI-resistance
mutations at positions 103, 181, and 190; and the PI-resistance
mutations at positions 48, 82, and 90. An analysis that
included these 56 sequences did not affect any of the
signiﬁcant ﬁndings in the study because these mutations
were so much more common in treated than in untreated
persons in multiple different subtypes (data not shown).
Statistical Analysis
Frequencies of mutations at each RT and protease codon
were analyzed by a binomial response model employing a
cube root transformation (similar to a logistic transform, with
higher accuracy for extreme values) to identify signiﬁcant
differences in polymorphisms and treatment-related muta-
tions between subtypes. Mutation frequencies for treated and
untreated persons were compared for each subtype (Figure
1). This analysis deﬁned three parameters: (i) a subtype
parameter (h1), comparing codons between untreated persons
infected with B and each of the non-B subtypes; (ii) a
treatment parameter (h2), comparing codons between treated
and untreated sequences of the same subtype; and (iii) an
interaction parameter (h3), comparing the effect of treatment
between subtype B and each of the non-B subtypes.
To increase the statistical power of our analysis, we made
two simpliﬁcations. First, we did not distinguish between
distinct substitutions at the same position; all differences
from consensus B were considered mutations. Second, viruses
were categorized only according to the classes of drugs (PI,
NRTI, NNRTI) to which they had been exposed.
To correct for multiple comparisons between subtype B
and each non-B subtype, signiﬁcant results included those z
values exceeding three in absolute value, according to a 0.05
Benjamini–Hochberg false discovery rate criterion [41]. This
method is a sequential Bonferroni-type procedure that is
appropriate for situations in which multiple statistically
signiﬁcant associations are expected. The coefﬁcients in the
binomial response model were ranked in ascending order,
and each hypothesis of rank r w a sc o m p a r e dw i t ha
signiﬁcance cutoff of 0.05 (false discovery rate) multiplied
by r/n, where n was 99 for the protease mutations and 240 for
the RT mutations (i.e., number of comparisons).
Figure 3. Proportions of Persons Receiving Treatment with Specific
NRTIs, NNRTIs, and PIs
The number of persons with non-B virus receiving the NRTI
tenofovir (ten), the NNRTI delavirdine (three), and the PIs ampre-
navir (13) and lopinavir (28) are not shown. 3TC, lamivudine; ABC,
abacavir; AZT, zidovudine; D4T, stavudine; DDC, zalcitabine; DDI,
didanosine; EFV, efavirenz; IDV, indinavir; NFV, nelﬁnavir; NVP,
nevirapine; RTV, ritonavir; SQV, saquinavir.
DOI: 10.1371/journal.pmed.0020112.g003
Figure 4. Subtype-Specific Polymorphisms
Positions in protease (left) and RT (right) at which mutation frequency varied signiﬁcantly between subtype B and at least one non-B subtype in
untreated persons. Positions are shown along the x-axes, and the frequency of mutation for each subtype is shown along the y-axes. Positions
related to drug resistance in subtype B are boxed. Bar colors denote statistical signiﬁcance: black is statistically signiﬁcant (Zh1   3); gray is
borderline signiﬁcant (1   Zh1 , 3); white is not statistically signiﬁcant (Zh1 , 1).
DOI: 10.1371/journal.pmed.0020112.g004
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HIV-1 Subtypes
Sequences were obtained from 3,686 persons, in 56
countries, infected with non-B HIV-1 subtypes (Figure 2;
Table 1), including 1,997 persons from whom both protease
and RT sequences were available, 908 persons from whom
only protease sequences were available, and 933 persons from
whom only RT sequences were available. Sequences from
untreated individuals were isolated between 1983 and 2003.
Sequences from treated individuals were isolated between
1993 and 2003. A total of 2,311 (82%) protease and 2,381
(83%) RT sequences were obtained from plasma samples. The
remaining sequences were obtained from peripheral blood
mononuclear cells.
Antiretroviral Treatments
Of the participants with non-subtype-B viruses, 1,533
(42%) were receiving antiretroviral drugs at the time of
sequencing: 1,140 were receiving NRTIs, 527 PIs, and 766
NNRTIs. According to subtype, 89% to 100% had received
one or more NRTIs, 22% to 76% had received one or more
PIs, and 32% to 55% had received one or more NNRTIs.
Among treated persons infected with subtype B viruses, 98%
had received NRTIs, 66% had received PIs, and 34% had
received NNRTIs (Figure 3).
Mutation Prevalence
Twenty-two (22%) protease and 87 (36%) RT positions
were conserved in all subtypes regardless of the presence or
absence of therapy. Twenty-four (24%) protease and 38 (16%)
RT positions were conserved in untreated persons but were
mutant in more than 1% of treated persons. The remaining
53 (53%) protease and 115 (48%) RT positions were
polymorphic, or mutant in more than 1% of untreated
persons.
To assess the impact of viral subtype and treatment on the
distribution of mutations in protease and RT, a binomial
response model using subtype and treatment as explanatory
variables was used to predict whether a position was wild-type
(matching the consensus B site) or mutant. This model
identiﬁed three types of positions: (i) positions in sequences
from untreated people more likely to be mutated in non-B
than in B subtypes (subtype-speciﬁc polymorphisms); (ii)
positions in sequences of the same subtype more likely to be
mutated in treated than in untreated people (subtype-speciﬁc
treatment-related positions); and (iii) positions for which the
effect of treatment differed signiﬁcantly between non-B and
B subtypes (subtype–treatment interactions).
Subtype-speciﬁc polymorphisms. Figure 4 shows the muta-
tion prevalence according to subtype for 37 protease and 41
RT subtype-speciﬁc polymorphisms (signiﬁcant h1; see Meth-
ods). Twenty-eight of the protease and 26 of the RT subtype-
speciﬁc polymorphisms were polymorphic in untreated
subtype B viruses, whereas nine of the protease and 15 of
t h eR Tw e r ec o n s e r v e di ns u b t y p eB .S u b t y p e - s p e c i ﬁ c
polymorphisms at conserved positions in untreated subtype
B viruses were generally present in a small number of
subtypes at low levels (,5%). Notable exceptions included
protease positions 45 and 74 and RT positions 40, 43, 104, 195
and 238.
Six subtype-speciﬁc polymorphisms in protease (positions
10, 20, 33, 36, 82, and 93) and ﬁve in RT (98, 116, 179, 227, and
238) occurred at sites known to be associated with drug
resistance in subtype B viruses. These positions (with the
exception of positions 116, 227, and 238 in RT) were also
polymorphic in subtype B. M184I was present in six mono-
phyletic CRF01_AE isolates from untreated persons [42,43]
and was therefore not considered to be a subtype-speciﬁc
polymorphism. These six sequences also displayed GﬁA
hypermutation [44], possibly explaining the M184I change
(ATGﬁATA) and further complicating the signiﬁcance of
this ﬁnding.
Subtype-speciﬁc polymorphisms at four protease and three
RT drug-resistance positions represented the consensus
sequence for at least one non-B subtype: K20I in subtypes G
and CRF02_AG, M36I in subtypes A, C, D, F, G, CRF01_AE
and CRF02_AG, V82I in subtype G, and I93L in subtype C
for protease; and A98S in subtype G, V179I in subtype A, and
K238R in CRF01_AE for RT. Each of the non-B subtypes was
signiﬁcantly more polymorphic than subtype B at protease
positions 20, 36, and 41 and RT positions 35, 39, and 207.
Subtype-speciﬁc treatment-related mutations. Figure 5
shows the mutation prevalence according to subtype for 31
protease and 36 RT subtype-speciﬁc treatment-related
positions signiﬁcantly more likely to be mutant in treated
than untreated persons in at least one non-B subtype
(signiﬁcant h2; see Methods). The protease positions included
16 of the 22 known PI resistance positions and 15 additional
treatment-related positions. The RT positions included 28 of
the known 33 RTI resistance positions and eight additional
treatment-related positions. Although each of the known PI-
and RTI-resistance positions occurred in at least one non-B
subtype, three of the 22 protease positions and ﬁve of the 33
RT positions included mutations that occurred too infre-
quently for a signiﬁcant association with treatment to be
detected in our analysis.
Of the 15 treatment-related protease positions not known
to be associated with drug resistance, eight were also
signiﬁcantly associated with treatment in subtype B viruses
(positions 13, 23, 43, 45, 62, 66, 74, and 85), and two have been
previously reported to be associated with treatment in
subtype B viruses (positions 22 and 83) [45]. The remaining
ﬁve subtype-speciﬁc treatment-related protease positions
included positions 6, 15, 19, 37 and 64, which—although
highly polymorphic in many subtypes—are associated with
treatment in subtype C (positions 6 and 64), CRF02_AG
Figure 5. Subtype-Specific Treatment-Related Mutations
Positions in protease (left) and RT (right) at which mutations were signiﬁcantly more prevalent in HIV-1 isolates from treated than from
untreated persons infected with the same subtype. Positions are shown along the x-axes, and the proportion of mutant sequences in treated
persons for each subtype is shown along the y-axes. For protease (left), treated persons are those receiving one or more PIs. For RT (right),
treated persons are those receiving one or more NRTIs. Positions related to drug resistance in subtype B are boxed. Bar colors denote statistical
signiﬁcance: black is statistically signiﬁcant (Zh2   3); gray is borderline signiﬁcant (1   Zh2 , 3); white is not statistically signiﬁcant (Zh2 , 1).
DOI: 10.1371/journal.pmed.0020112.g005
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Subtype and Drug Impact on Genotype(position 15), subtype F (position 19), subtype A (position 37),
and CRF01_AE (position 64).
Of the eight treatment-related RT positions at sites not
known to be associated with drug resistance, seven were also
signiﬁcantly associated with treatment in subtype B viruses
(positions 68, 203, 208, 218, 221, 223, and 228) and one
(position 102) was associated with treatment in subtype C but
not B.
Subtype–treatment interactions. The subtype of the se-
quence signiﬁcantly inﬂuenced the effect of treatment
(signiﬁcant h3; see Methods) on 20 protease positions (10,
12, 13, 14, 15, 20, 37, 53, 62, 63, 64, 65, 67, 71, 73, 74, 77, 82, 88,
and 89) and 11 RT positions (35, 39, 48, 98, 104, 106, 121, 162,
166, 179, and 238). For example, RT position 98 was mutant in
7% of untreated and 16% of treated persons with subtype B
viruses (approximately 2-fold difference) and in 1% of
untreated and 14% of treated persons with CRF01_AG
viruses (14-fold difference). Other positions less likely to be
mutated in subtype B than in non-B viruses in response to
treatment included protease residues 14 (subtype A); 13 and
64 (subtype C); 37 and 65 (subtype F); 71 (subtype G); 62 and
64 (CRF01_AE); and 15 and 71 (CRF02_AG); and RT
residues 35 (subtype A); 98 and 106 (subtype C); 35 and 98
(subtype G); and 98 (CRF02_AG).
At other positions, treatment had a larger effect on subtype
B viruses than on one or more non-B subtypes. For example,
protease position 20 was mutant in 2% of untreated and 24%
of treated persons with subtype B viruses (approximately 12-
fold increase with treatment) and in 11% of untreated and
42% of treated persons with subtype C viruses (approx-
imately 4-fold increase with treatment). These positions
included protease residues 10, 20, and 63 (subtype A); 20,
53, 63, 74, and 82 (subtype C); 13 and 20 (subtype D); 10, 14,
20, and 77 (subtype F); 20, 67, 73, 82, and 88 (subtype G); 20,
63, 82, and 89 (CRF01_AE); and 20 (CRF02_AG); and RT
residues 39 and 179 (subtype A); 35, 48, 121, and 166 (subtype
C); 39 (subtype D); 39 (subtype F); 39 and 104 (subtype G); 162
and 238 (CRF01_AE); and 39 (CRF02_AG).
These 31 positions with subtype–treatment interactions
included 12 known drug-resistance positions. Of these, seven
protease (10, 20, 53, 63, 77, 82, and 88) and two RT (179 and
238) resistance positions were more likely to be mutated in
subtype B than in one or more non-B subtypes in response to
treatment. One protease position (71) and two RT positions
(98 and 106) were more likely to be mutated in one or more
non-B subtypes.
Known Drug-Resistance Mutations
Figure 6 shows the amino acid substitutions present at
drug-resistance positions in protease and RT sequences from
untreated and treated persons infected with B and non-B
subtypes. Fourteen of the 22 known PI-resistance positions
occurred in subtype A, 20 in subtype C, 16 in subtype D, 20 in
subtype F, 18 in subtype G, 17 in CRF01_AE, and 17 in
CRF02_AG. Thirteen of the 18 known NRTI-resistance
positions occurred in subtype A, 18 in subtype C, 13 in
subtype D, 15 in subtype F, 18 in subtype G, 18 in CRF01_AE,
and 16 in CRF02_AG. Ten of the 15 known NNRTI-
resistance positions occurred in subtype A, 15 in subtype C,
11 in subtype D, 13 in subtype F, 14 in subtype G, 13 in
CRF01_AE, and 12 in CRF02_AG.
In all, 106 of 113 (94%) different amino acid substitutions
at 55 known subtype B drug-resistance positions (22 protease
and 33 RT) were also present in at least one non-B subtype. In
an exploratory analysis, which was not controlled for multiple
comparisons, the frequencies of 24 mutations at 14 protease
positions and 32 mutations at 19 RT positions differed
between subtype B and one or more non-B subtypes.
Discussion
This collaborative analysis was designed to determine
whether and to what degree the genetic mechanisms of HIV
drug resistance are shared between subtype B and non-B
viruses. Mutations responsible for drug resistance in subtype
B viruses have been characterized by three types of studies: (i)
those that identify mutations selected in viruses of persons
receiving antiretroviral therapy, (ii) those that quantify the
effect of speciﬁc mutations on in vitro drug susceptibility,
and (iii) those that examine the effectiveness of treatment
regimens in persons with viruses containing known or
suspected drug-resistance mutations. This study, which
identiﬁes mutations arising in non-B viruses during antire-
troviral therapy, is a necessary step for designing laboratory
and clinical studies of potential drug-resistance mutations.
Do the known subtype B drug-resistance mutations also
occur in non-B subtypes? We found that each of the 55 known
subtype B drug-resistance mutations occurred in at least one
non-B isolate. Of these, 44 (80%) were signiﬁcantly associated
with drug therapy in non-B isolates. The remaining 11
mutations were uncommon in subtype B and all non-B
subtypes, making it difﬁcult to determine whether they were
also signiﬁcantly associated with therapy. Phenotypic sus-
ceptibility testing of non-B viruses with treatment-selected
mutations is necessary to conﬁrm and quantify the contribu-
tion of these mutations to drug resistance in the genetic
context in which they arise.
Do non-subtype B viruses from persons with virologic
failure develop novel mutations? Fifteen protease and eight
RT positions not generally considered to be drug-resistance
positions were signiﬁcantly associated with treatment in at
least one non-B subtype. However, mutations at 17 of these 23
positions were also associated with treatment in subtype B
viruses. Therefore, of the 67 mutations associated with
Figure 6. Amino Acid Differences from Consensus B Sequence at Drug-Resistance Positions in Protease and RT according to Subtype
(A) shows data for protease, and (B) shows data for RT. In both, the ﬁrst line lists the drug-resistance positions. The second line shows single-
letter amino acid codes for the consensus B sequence. For each subtype (left column), the percentage of speciﬁc mutations in untreated persons
is shown above the dashed line, whereas the percentage of speciﬁc mutations in treated persons is shown below the dashed line. Positions with
signiﬁcant differences in mutation frequency between B and non-B subtypes (p , 0.01, according to v
2 test with Yate’s correction) are circled. A
pound sign indicates an insertion.
DOI: 10.1371/journal.pmed.0020112.g006
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Subtype and Drug Impact on Genotypetreatment in at least one non-B subtype, 61 were also
associated with treatment in subtype B. For the six mutations
associated with therapy in at least one non-B subtype but not
in subtype B, the associations were at the borderline of
signiﬁcance and require conﬁrmation.
Among untreated persons, non-B subtype-speciﬁc poly-
morphisms occurred at 37 protease and 41 RT positions.
Most of these non-B polymorphic positions are also poly-
morphic in subtype B viruses, and several act as accessory
drug-resistance mutations in subtype B viruses. Phenotypic
susceptibility testing of non-B viruses with such polymorphic
accessory mutations is needed to conﬁrm that these naturally
occurring viruses are fully susceptible to current antiretro-
virals—a supposition that appears be true based on the
excellent virologic responses of non-B viruses to antiretro-
viral treatment in observational studies.
We made two simpliﬁcations in this study to increase the
statistical power of our analyses. These will become unneces-
sary in future analyses as sufﬁcient numbers of sequences
from persons with well characterized treatment histories
become available. First, we did not distinguish between
different substitutions at the same position; all differences
from consensus B were considered mutations. Second, viruses
were classiﬁed only by the classes of drugs to which they were
exposed rather than by individual drugs or drug regimens.
Therefore, our analyses could not detect differences between
subtype B and other subtypes that depend on speciﬁc
mutations or speciﬁc drugs. Indeed, two such differences
have been reported: (i) V106M is the most common
substitution at RT position 106 in subtype C viruses whereas
V106A predominates in subtype B viruses [33,35,46], and (ii)
although the protease mutations D30N and L90M both
develop in non-B viruses during nelﬁnavir therapy, D30N
occurs more commonly in subtype B, whereas L90M occurs
more commonly in subtypes C, G, and CRF01_AE
[17,34,47,48].
Although the clinical samples in this study were originally
obtained for a variety of purposes, including clinical manage-
ment, the sequences of these samples represent experiments
of nature that reveal the mutations associated with continued
HIV-1 replication in the presence of selective antiretroviral
therapy. The accurate identiﬁcation of treatment-related
mutations in such a cross-sectional analysis is challenging,
however, because misclassiﬁcation can result from the trans-
mission of drug-resistant viruses, differences in speciﬁc HIV-
1 variants among different human populations (population
stratiﬁcation), and the many statistical comparisons required
as a result of HIV-1 sequence variability.
The transmission of drug-resistant HIV-1 viruses weakens
cross-sectional analyses because some untreated persons may
have been infected with viruses already containing treatment-
related mutations. To mitigate this effect, we excluded
isolates from untreated persons containing two or more
non-polymorphic known drug-resistance mutations, because
this pattern is not consistent with natural sequence variation.
However, as noted in the Methods, an analysis that included
these isolates did not alter any of the signiﬁcant ﬁndings in
the study. Conversely, the possibility that resistance muta-
tions transmitted between persons in our dataset inﬂated the
amount of resistance among persons receiving treatment was
mitigated by excluding any isolate differing from another
isolate at less than 1% of its nucleotides.
HIV-1 evolution is driven by genetic drift, immunologic
pressure, and selective drug pressure. Population stratiﬁca-
tion can be a confounding factor when viral lineages with
different founder mutations (resulting from drift or immu-
nologic pressure) are exposed to different degrees of
antiretroviral selection pressure. To distinguish mutations
developing in multiple individuals as a result of selective drug
pressure from mutations originating in a fewer number of
founder viruses, we reconstructed the ancestral sequences at
each node of a phylogenetic tree for each subtype and
counted the number of times each mutation was predicted to
have developed within that subtype. Because of the limited
ability of phylogenetic methods to estimate accurate trees for
large numbers of related sequences (i.e., belonging to the
same HIV-1 subtype), only those positions for which the
majority of mutations ( 75%) appeared to result from new
mutations were considered to be selected by antiretroviral
therapy.
Because this analysis was, to our knowledge, the ﬁrst to
simultaneously examine all protease and most polymerase-
coding RT positions in multiple subtypes, and because
multiple associations between mutation and treatment were
expected, we used a relatively lenient correction for
multiple comparisons in order to minimize the number of
missed associations. Nonetheless, of the 67 positive associ-
ations detected in this study, 61 were also present in
persons with subtype B viruses and have previously been
reported [45,49].
In conclusion, most of the protease and RT positions
associated with drug resistance in subtype B viruses are
selected by antiretroviral therapy in one or more non-B
subtypes as well. Conversely, we found no evidence that non-
B viruses develop resistance by mutations at positions that
are not associated with resistance in subtype B viruses. Based
on currently available data, global surveillance efforts and
genotypic assessments of drug resistance should focus
primarily on the known subtype B drug-resistance muta-
tions.
Supporting Information
Dataset S1. List of GenBank Accession Numbers for Non-Subtype-B
Sequences Used in This Study
Found at DOI: 10.1371/journal.pmed.0020112.sd001 (59 KB PDF).
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank/) isolates and
accession numbers for the reference subtype specimens discussed in
this paper are U455/subtype A (M62320), HXB2/subtype B (K03455),
C2220/subtype C (U46016), NDK/subtype D (M27323), 93BR020/
subtype F (AF005494), SE6165/subtype G (AF061642), 90CR056/
subtype H (AF005496), SE9173c/subtype J (AF082394), 97EQTB11C/
subtype K (AJ249235), CM240/CRF01_AE (U54771), IbNG/
CRF02_AG (L39106), YBF30/Group N (AJ006022), and ANT70C/
Group O (L20587). The accession numbers for the non-subtype-B
sequences used in this study are listed in Dataset S1.
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Patient Summary
Background There are many different subtypes of HIV-1. The most
common one in more developed countries is subtype B and that is the
one which has been studied most and used in drug development.
However, worldwide, other subtypes are more frequent. All HIV-1
subtypes acquire mutations, and some of these cause resistance to the
drugs used to treat HIV. It is not clear whether the same mutations that
cause drug resistance to subtype B virus are also important in causing
resistance to non-subtype-B viruses.
What Did the Researchers Do? They compared the viral sequences of
3,686 people with non-subtype-B HIV, and 4,769 with subtype B virus, all
with known treatment histories. They found that the mutations known
to cause drug resistance in subtype B virus also occur in non-subtype B,
and the majority of mutations in non-subtype B also occur in subtype B.
What Do These Findings Mean? It seems that largely the same
mutations occur in both subtype B and non-subtype-B viruses. However,
some mutations were only present in low numbers, so more work will
need to be done before their role is clear. Also, the authors did not look
at mutations and their relation to each different drug a patient had—
only the general type of drug. Nor did they look at what happens when
different mutations occur at one place in a virus. However, for now the
current strategy of focusing on assessing the mutations seen in subtype
B virus seems a reasonable approach to take when assessing surveillance
of drug resistance while more work is done to follow up these findings.
Where Can I Get More Information? TheBody.com has a section on
drug resistance: http://www.thebody.com/treat/resistance.html
The Aidsmap Web site has many patient information sheets, including on
resistance: http://www.aidsmap.com
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